International Immunology, Vol. 16, No. 2, pp. 205-213,
February 2004
© 2004 Japanese Society for Immunology
Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis
1 Division of Immunology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA 2 Immunopathology Unit, Massachusetts General Hospital, Boston, MA 02114, USA 3 Inflammation Division, Millennium Pharmaceuticals Inc., Cambridge, MA 02139, USA
Correspondence to: C. Terhorst; E-mail: terhorst{at}bidmc.harvard.edu
Transmitting editor: W. Strober
Several autoimmune disease models depend on an imbalance in the activation of aggressor Th1 and CD4+CD25+ regulatory T (Treg) cells. Here we compare the requirement for signals through the co-stimulatory molecules CD28 and inducible co-stimulator (ICOS) in chronic murine colitis, a model for inflammatory bowel disease. We used a colitis model in which disease-causing CD45RBhi T cells alone or in combination with CD4+CD25+ T cells from either CD28-deficient or wild-type donors were transferred into T cell-deficient animals, half of which were treated with ICOS-blocking reagents. Blocking ICOS on the surface of CD28-deficient Th1 cells abrogated development of colitis, whereas blocking CD28 or ICOS alone had little to no effect on disease induction. In contrast to Th1 cells, regulatory T cell functioning depended mostly on CD28 signaling with only a minor contribution for ICOS. We conclude that CD28 and ICOS collaborate to development of murine colitis by aggressor Th1 cells, and that CD28 is required for Treg cells, which should caution against the use of CD28-blocking reagents in inflammatory bowel disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Takahashi, K. Matsumoto, H. Saito, T. Nanki, N. Miyasaka, T. Kobata, M. Azuma, S.-K. Lee, S. Mizutani, and T. Morio Impaired CD4 and CD8 Effector Function and Decreased Memory T Cell Populations in ICOS-Deficient Patients J. Immunol., May 1, 2009; 182(9): 5515 - 5527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, M. J. Szczepanski, S. Lang, J. M. Kirkwood, and T. L. Whiteside Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression J. Immunol., March 1, 2008; 180(5): 2967 - 2980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Marks, M. Verolin, A. Stensson, and N. Lycke Differential CD28 and Inducible Costimulatory Molecule Signaling Requirements for Protective CD4+ T-Cell-Mediated Immunity against Genital Tract Chlamydia trachomatis Infection Infect. Immun., September 1, 2007; 75(9): 4638 - 4647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Beier, T. Kallinich, and E. Hamelmann T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease Eur. Respir. J., August 1, 2007; 30(2): 383 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Wilson, C. Zaph, M. Mohrs, A. Welcher, J. Siu, D. Artis, and C. A. Hunter B7RP-1-ICOS Interactions Are Required for Optimal Infection-Induced Expansion of CD4+ Th1 and Th2 Responses J. Immunol., August 15, 2006; 177(4): 2365 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Riley and C. H. June The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation Blood, January 1, 2005; 105(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|